US OptionsDetailed Quotes
TRVN250321C2500
- 0.05
- 0.000.00%
15min DelayClose Aug 12 16:00 ET
0.00High0.00Low
0.00Open0.05Pre Close0 Volume75 Open Interest2.50Strike Price0.00Turnover89.34%IV50.89%PremiumMar 21, 2025Expiry Date0.00Intrinsic Value100Multiplier57DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1802Delta0.4403Gamma33.80Leverage Ratio-0.0014Theta0.0004Rho6.09Eff Leverage0.0018Vega
Trevena Stock Discussion
Sign in to post a comment
30 Stocks below $2 to watch out for high risk high return.
Pharmaceutical: $Esperion Therapeutics (ESPR.US)$ $Seelos Therapeutics (SEEL.US)$ $Scilex Holding (SCLX.US)$ $Trevena (TRVN.US)$ $111 Inc (YI.US)$ $Cue Biopharma (CUE.US)$
Frac Sand: $Smart Sand (SND.US)$
Graphite Electrode: $GrafTech (EAF.US)$
Crypto Mining: $Bit Origin (BTOG.US)$
Artificial Intelligence: $Veritone (VERI.US)$
IOT Security: $Gorilla Technology (GRRR.US)$
Holographic: $WiMi Hologram Cloud (WIMI.US)$
Real Est...
Pharmaceutical: $Esperion Therapeutics (ESPR.US)$ $Seelos Therapeutics (SEEL.US)$ $Scilex Holding (SCLX.US)$ $Trevena (TRVN.US)$ $111 Inc (YI.US)$ $Cue Biopharma (CUE.US)$
Frac Sand: $Smart Sand (SND.US)$
Graphite Electrode: $GrafTech (EAF.US)$
Crypto Mining: $Bit Origin (BTOG.US)$
Artificial Intelligence: $Veritone (VERI.US)$
IOT Security: $Gorilla Technology (GRRR.US)$
Holographic: $WiMi Hologram Cloud (WIMI.US)$
Real Est...
12
2
5
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities.
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company dedicated to developing and commercializing innovative medicines for patients with central nervous system (CNS) disorders, has recently announced a amendment to its March 2022 ex-US royalty-based financing agreement with R-Bridge Healthcare Fund, L.P. (R-Bridge). This development repr...
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company dedicated to developing and commercializing innovative medicines for patients with central nervous system (CNS) disorders, has recently announced a amendment to its March 2022 ex-US royalty-based financing agreement with R-Bridge Healthcare Fund, L.P. (R-Bridge). This development repr...
1
$Trevena (TRVN.US)$ Trevena Inc: Expects a $10 Mln Reduction in Liabilities Associated With Its Ex-US Royalty Financing
1
6
$Trevena (TRVN.US)$
Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing
Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing
1
$Trevena (TRVN.US)$ Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection With Existing Ex-US Royalty Financing
1
2
$Trevena (TRVN.US)$ daily volume remains consistently low, and price is relatively stable.
Waiting game….![]()
![]()
Waiting game….
No comment yet
Tonyco : $bluebird bio (BLUE.US)$
$X4 Pharmaceuticals (XFOR.US)$
$Edible Garden (EDBL.US)$
HailTheApocalypse Tonyco : I would scratch out Blueturd.